HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yin, D. Articles by Chong, A. S.-F. Search for Related Content PubMed PubMed Citation Articles by Yin, D. Articles by Chong, A. S.-F.

Intact Active Bone Transplantation Synergizes with Anti-CD40 Ligand Therapy to Induce B Cell Tolerance¹

Department of General Surgery, Rush Presbyterian Hospital, St. Luke’s Medical Center, Chicago, IL 60612

Blockade of T cell costimulatory pathways can result in the prolongation of allograft survival through the suppression of Th1 responses; however, late allograft rejection is usually accompanied by an emerging allograft-specific humoral response. We have recently determined that intact active bone (IAB) fragments transplanted under the kidney capsule can synergize with transient anti-CD40 ligand (CD40L) treatment to induce robust donor-specific allograft tolerance and suppress the alloantibody response. In this study, we take advantage of the ability of galactosyltransferase-deficient knockout (GT-Ko) mice to respond to the carbohydrate epitope, galactose-1,3-galactose (Gal), to investigate whether IAB plus transient anti-CD40L therapy directly tolerize B cell responses. GT-Ko mice tolerized to Gal-expressing C3H hearts and IAB plus transient anti-CD40L therapy were challenged with pig kidney membranes that express high levels of Gal. The anti-Gal IgM and IgG responses were significantly suppressed in IAB-tolerant mice compared with controls, while the non-Gal anti-pig Ab responses were comparable. The anti-pig T cell cytokine response (IFN- and IL-4) was comparable in IAB-tolerant and control mice. The tolerant state for the anti-Gal IgM response could be reversed with repeated immunization, whereas the tolerant state for the IgG response was robust and resisted repeated immunization. These observations provide an important proof-of-concept that adjunct therapies can synergize with anti-CD40L Abs to tolerize B cell responses independent of their effects on T cells. This model, which does not require mixed chimerism, provides a unique opportunity for investigating the mechanism of peripheral tolerance in a clinically relevant population of carbohydrate-specific B cells.

This article has been cited by other articles:

				H. Wang, W. Ge, J. Arp, R. Zassoko, W. Liu, T. E. Ichim, J. Jiang, A. M. Jevnikar, and B. Garcia Free Bone Graft Attenuates Acute Rejection and in Combination with Cyclosporin A Leads to Indefinite Cardiac Allograft Survival J. Immunol., May 15, 2009; 182(10): 5970 - 5981. [Abstract] [Full Text] [PDF]

				Y. Li, L. Ma, D. Yin, J. Shen, and A. S. Chong Long-Term Control of Alloreactive B Cell Responses by the Suppression of T Cell Help J. Immunol., May 1, 2008; 180(9): 6077 - 6084. [Abstract] [Full Text] [PDF]

				Y. Li, L. Ma, J. Shen, and A. S. Chong Peripheral deletion of mature alloreactive B cells induced by costimulation blockade PNAS, July 17, 2007; 104(29): 12093 - 12098. [Abstract] [Full Text] [PDF]

				D. Yin, N. Dujovny, L. Ma, A. Varghese, J. Shen, D. K. Bishop, and A. S. Chong IFN-{gamma} Production Is Specifically Regulated by IL-10 in Mice Made Tolerant with Anti-CD40 Ligand Antibody and Intact Active Bone J. Immunol., January 15, 2003; 170(2): 853 - 860. [Abstract] [Full Text] [PDF]